Emergent BioSolutions (EBS) Cash & Equivalents Growth (1y) (2011 - 2026)
Emergent BioSolutions (EBS) Cash & Equivalents Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 69.13% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 2.86% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 19.56% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 13.19% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 56.51% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 25.91% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -1.67% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | -4.65% |
| 10 | Emergent BioSolutions | 251.81 Mn | 110.91 Mn | 137.20 Mn | -47.74% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -47.74% |
| Mar 31, 2026 | 7.51% |
| Dec 31, 2025 | 106.43% |
| Sep 30, 2025 | 63.78% |
| Jun 30, 2025 | 283.50% |
| Mar 31, 2025 | 89.94% |
| Dec 31, 2024 | -10.92% |
| Sep 30, 2024 | 70.73% |
| Jun 30, 2024 | -21.33% |
| Mar 31, 2024 | -81.75% |
| Dec 31, 2023 | -82.62% |
| Sep 30, 2023 | -63.55% |
| Jun 30, 2023 | -75.26% |
| Mar 31, 2023 | -1.28% |
| Dec 31, 2022 | 11.54% |
| Sep 30, 2022 | -40.34% |
| Jun 30, 2022 | -19.98% |
| Mar 31, 2022 | -20.45% |
| Dec 31, 2021 | -7.28% |
| Sep 30, 2021 | -2.70% |